Epigen Pharmaceuticals Overview

  • Founded
  • 2013
Founded
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Epigen Pharmaceuticals General Information

Description

Developer of cardiac reperfusion therapies designed to prevent ischemia-reperfusion injury. The company's therapies involves the use of histone deacetylase (HDAC) inhibitors for reducing myocardial infarct size following acute myocardial infarction and restoring normal blood flow, thereby assisting physicians with an effective pharmaceutical intervention for protecting the cardiomyocyte from reperfusion injury.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Therapeutic Devices
Primary Office
  • 3160 Chestnut Street Suite- 200
  • Philadelphia, PA 19104
  • United States
+1 (215) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Epigen Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 17-Sep-2020 Completed Out of Business
1. Accelerator/Incubator 01-Jan-2014 Completed Startup
To view Epigen Pharmaceuticals’s complete valuation and funding history, request access »